Gambia has launched an urgent door-to-door campaign to remove cough and cold syrups blamed for the deaths of 66 children from kidney injury in the tiny West African country.
Speaking to The Associated Press, the Director of Health Dr. Mustapha Bittaye confirmed the wave of child deaths from acute kidney injury, sending shockwaves across the country of 2.4 million people and around the world.
The World Health Organisation has issued an alarm in response to the deaths.
WHO has issued a medical product alert for four contaminated medicines identified in The Gambia that have been potentially linked to acute kidney injuries and 66 deaths among children, WHO Director-General Tedros Adhanom Ghebreyesus said in a statement issued on Wednesday.
The loss of young lives is beyond heartbreaking for their families, he said.
The four medicines are cough and cold syrups produced in India, said the WHO statement.
While the contaminated products have so far only been detected in Gambia, they may have been distributed to other countries, said the statement.
WHO is pursuing investigations with the company and regulatory authorities in India, it said.
"WHO recommends all countries detect and remove these products from circulation to prevent further harm to patients, it said.
Teaming up with the Gambia Red Cross Society, the Ministry of Health has dispatched hundreds of young people to collect the suspect syrups through a house-to-house campaign.
Gambia's Medical Research Council has also issued an alarm.
Over the last week, we admitted a child with this condition (acute kidney injury) ... and she has unfortunately died. We were able to confirm that she had taken one of the drugs that is suspected to be causing this, prior to her arrival at our clinic. It had been bought at a pharmacy within The Gambia, the council said in a statement.
The drug has been identified as containing a significant amount of a toxin which damages kidneys irreversibly.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)